Blood test may help choose best retreatment for colorectal cancer
NCT ID NCT07536113
First seen Apr 19, 2026 · Last updated May 01, 2026 · Updated 3 times
Summary
This study looks at whether a simple blood test (ctDNA) can help doctors decide if it's safe and effective to retreat patients with metastatic colorectal cancer using a targeted therapy called anti-EGFR. Researchers will collect and analyze data from 250 patients who have already had this blood test as part of another trial. The goal is to see if the blood test results can predict who will benefit from retreatment, without giving any new treatment directly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER (CRC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ASST GOM Niguarda
RECRUITINGMilan, Italia, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.